FDA OKs Regeneron and Sanofi's Dupixent for younger patients with atopic dermatitis

|About: Regeneron Pharmaceutic... (REGN)|By:, SA News Editor

The FDA approves Regeneron Pharmaceuticals (REGN +2.1%) and development partner Sanofi's (SNY +1.3%) Dupixent (dupilumab) for patients ages 12 - 17 with moderate-to-severe atopic dermatitis (eczema) who have failed to respond adequately to topical therapies.

The FDA approved the med to treat adults with eczema two years ago.

Subscribe for full text news in your inbox